Skip to content

Impact of TAVI on Cognition, Mood and Health-related Quality of Life

The Impact of Transcatheter Aortic Valve Implantation on Cognition, Mood and Health-related Quality of Life - an Explorative Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04371172
Enrollment
128
Registered
2020-05-01
Start date
2023-02-20
Completion date
2025-05-29
Last updated
2023-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment

Brief summary

In the proposed study, patients with and without embolic protection devices during Transcatheter Aortic Valve Implantation will be repeatedly examined with a comprehensive psychiatric and cognitive test battery over a post-interventional period of 6 months after TAVI, with regard to the effects on mood, cognitive Performance and health-related Quality of life.

Detailed description

The percutaneous aortic valve replacement (TAVI, Transcatheter Aortic Valve Implantation) enables the implantation of a new biological aortic valve at the beating heart. The procedure is performed under local anaesthesia and is a gold standard in the therapy of aortic stenosis, especially in patients with a too high health risk for cardiovascular surgery. In the proposed study, patients with and without embolic protection devices during TAVI will be repeatedly examined with a comprehensive psychiatric and cognitive test battery over a post-interventional period of 6 months after TAVI, with regard to the effects on mood, cognitive Performance and health-related quality of life.

Interventions

OTHERcognitive research battery, MRI, laboratory values

cognitive research battery, MRI, laboratory values

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Written declaration of consent of the study participants to participate in the study after detailed information on the nature, significance, risks and scope of the study. * Women and men between the ages of 19 and 90 * Clinical indication for TAVI intervention * No previous psychiatric illness before TAVI * No other serious disease affecting the immune system

Exclusion criteria

* Non-compliance with the inclusion criteria * Persons unable to give consent (e.g. dementia, delirium etc.) * Magnetic resonance imaging (MR) contraindications * ophthalmological inability to read

Design outcomes

Primary

MeasureTime frameDescription
cognition12 monthsMontreal-Cognitive-Assessment, cognitive test battery

Secondary

MeasureTime frameDescription
health-related quality of life12 monthsShort Form (36) Health Survey (SF-36): The SF-36 consists of 8 scales. scores. Each scale is directly transformed into a 0-100 scale. A score of 100 is equivalent to no disability.

Other

MeasureTime frameDescription
mood12 monthsHospital Anxiety and Depression Scale (HADS): A person can score between 0 and 21 for either anxiety or depression); Montgomery-Åsberg Depression Rating Scale: usual cutoff points are: 0 to 6 - normal, 7 to 19 - mild depression, 20 to 34 - moderate depression, \>34 - severe Depression
MRI12 monthsMRI

Countries

Austria

Contacts

Primary ContactAndreas Baranyi, Prof.
an.baranyi@medunigraz.at0043-316-385-86241
Backup ContactAlbrecht Schmidt, PD.
albrecht.schmidt@klinikum-graz.at0043-316-385

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026